Diagnostic imaging systems such as CT/PET and MR/PET, which bring together in vivo anatomical and functional information in the same device or at the same workstation, offer a real opportunity for expanding the clinical utility of molecular imaging. But to drive adoption of these new combination systems will require data showing that their use changes therapeutic decision-making. For the most part, these data are at least several years away, with most of the work today in cancer, where in vivo imaging has been shown to better evaluate tumor type, guide radiation therapy, and change chemotherapy management. In the meantime, suppliers of imaging equipment to hospitals and research institutions are collaborating with academics and companies that are developing new radiotracers and other molecular probes. Such moves are not typical for these organizations, which, like IVD companies, traditionally have placed their bets on selling products into mature markets, rather than innovative R&D-oriented projects.
by Mark L. Ratner
A new commercially viable diagnostic imaging modality arrives every ten years or so. In the 1970s it was ultrasound, in...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
